A Phase 2 interventional study of Trastuzumab deruxtecan in Non-Small Cell Lung Cancer, sponsored by Daiichi Sankyo. Terminated at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by Daiichi Sankyo · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung — 5 open to participants now, 9 under way, 2 of them phase 3. trastuzumab deruxtecan · Carcinoma, Non-Small-Cell Lung.
Among the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 2, and was the 2nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →5 of the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Daiichi Sankyo · Sites in United States, Argentina, Belgium and 21 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Belgium and 16 more countries
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 20+
Centre Leon Berard · Sites in France
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 2
First in 2017; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 181 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 167 across the 12 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 6 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo: 5 open now, 16 under way, 5 of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo, this one is the 16th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 10 in phase 2, and was the 18th registered.
Daiichi Sankyo’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
3 of the studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06250777Yonsei UniversityEfficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases | 2026-12 |
| NCT07012031National Cancer Institute (NCI)Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation | 2027-06-14 |
| NCT04686305AstraZenecaPhase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Daiichi Sankyo’s 41 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in HER2-overexpressing and/or HER2-mutated advanced NSCLC participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has history of any disease, condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with HER2-overexpressing(immunohistochemistry \[IHC\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
Drug: Trastuzumab deruxtecan
Participants with HER2-overexpressing (immunohistochemistry \[IHC\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).
Drug: Trastuzumab deruxtecan
Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
Drug: Trastuzumab deruxtecan
Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.
Also known as: DS-8201a, Experimental product
Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by independent central review (ICR) committee based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on ICR is reported.
Time frame: From screening, up to 36 months (data cut-off)
Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on investigator assessment is reported.
Time frame: From screening, up to 36 months (data cut-off)
Duration of Response (DoR) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on independent central review and investigator assessment is reported.
Time frame: From screening to documented tumor progression or death from any cause, up to 36 months (data cut-off)
Progression-Free Survival (PFS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
Progression-free survival (PFS) was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. PFS based on independent central review and investigator assessment is reported.
Time frame: From date of enrollment to first objective radiographic tumor progression or death from any cause,, up to 36 months (data cut-off)
Overall Survival (OS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause.
Time frame: From date of enrollment to death from any cause, up to 36 months (data cut-off)
Percentage of Participants With Disease Control Rate (DCR) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
Disease Control Rate (DCR) was defined as the percentage of participants who achieved a best overall response of CR, PR, or stable disease (SD) during study treatment. Confirmation of CR/PR was required. DCR based on independent central review and investigator assessment is reported.
Time frame: From first dose, up to 36 months (data cut-off)
A total of 181 participants were enrolled and treated at clinic centers in Japan, United States, France, Netherlands, and Spain.
| Milestone | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated |
|---|---|---|---|
| Started | 49 | 41 | 91 |
| Completed | 0 | 0 | 0 |
| Not completed | 49 | 41 | 91 |
| Withdrew: Progressive disease | 24 | 17 | 43 |
| Withdrew: Clinical progression | 6 | 8 | 3 |
| Withdrew: Adverse event | 12 | 6 | 28 |
| Withdrew: Withdrawal by subject | 1 | 3 | 7 |
| Withdrew: Physician decision | 1 | 1 | 2 |
| Withdrew: Death | 4 | 5 | 6 |
| Withdrew: Other reasons | 1 | 1 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 |
The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by independent central review (ICR) committee based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on ICR is reported.
| Percentage of Participants | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated |
|---|---|---|---|
| Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC) | 26.5 (15.0 to 41.1) | 34.1 (16.1 to 45.5) | 54.9 (44.2 to 65.4) |
The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on investigator assessment is reported.
| Percentage of Participants | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated |
|---|---|---|---|
| Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC) | 28.6 (16.6 to 43.3) | 31.7 (18.1 to 48.1) | 61.5 (50.8 to 71.6) |
Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on independent central review and investigator assessment is reported.
| months | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated |
|---|---|---|---|
| Independent Central Review | 5.8 (4.3 to NA) | 4.7 (4.0 to NA) | 9.3 (5.7 to 14.7) |
| Investigator Assessment | 5.8 (4.7 to 11.3) | 7.0 (4.2 to NA) | 11.7 (7.2 to 16.9) |
Progression-free survival (PFS) was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. PFS based on independent central review and investigator assessment is reported.
| months | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated |
|---|---|---|---|
| Independent Central Review | 5.7 (2.8 to 7.2) | 6.7 (4.5 to NA) | 8.2 (6.0 to 11.9) |
| Investigator Assessment | 5.7 (3.8 to 7.2) | 7.2 (4.1 to 8.4) | 9.3 (7.1 to 14.0) |
Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause.
| months | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated |
|---|---|---|---|
| Overall Survival (OS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC) | 12.4 (7.8 to 17.2) | NA (6.7 to NA) | 17.8 (13.8 to 22.1) |
Disease Control Rate (DCR) was defined as the percentage of participants who achieved a best overall response of CR, PR, or stable disease (SD) during study treatment. Confirmation of CR/PR was required. DCR based on independent central review and investigator assessment is reported.
| Percentage of Participants | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated |
|---|---|---|---|
| Independent Central Review | 68.9 (53.4 to 81.8) | 77.5 (61.6 to 89.2) | 93.0 (85.4 to 97.4) |
| Investigator Assessment | 75.5 (61.1 to 86.7) | 78.0 (62.4 to 89.4) | 94.5 (87.6 to 98.2) |
Collected over Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, up 36 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: HER2 Overexpressing | 42/49 (85.7%) | 28/49 (57.1%) | 46/49 (93.9%) |
| Cohort 1a: HER2 Overexpressing | 32/41 (78%) | 18/41 (43.9%) | 41/41 (100%) |
| Cohort 2: HER2 Mutated | 72/91 (79.1%) | 40/91 (44%) | 91/91 (100%) |
| Event | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated |
|---|---|---|---|
| Disease ProgressionGeneral disorders | 6/49 | 4/41 | 7/91 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/49 | 2/41 | 1/91 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 4/49 | 2/41 | 7/91 |
| PneumoniaInfections and infestations | 4/49 | 1/41 | 2/91 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/49 | 2/41 | 1/91 |
| Respiratory Tract InfectionInfections and infestations | 1/49 | 2/41 | 0/91 |
| NauseaGastrointestinal disorders | 2/49 | 0/41 | 1/91 |
| VomitingGastrointestinal disorders | 1/49 | 1/41 | 3/91 |
| SeizureNervous system disorders | 1/49 | 0/41 | 3/91 |
| Interstitial Lung DiseaseRespiratory, thoracic and mediastinal disorders | 0/49 | 0/41 | 3/91 |
| Event | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated |
|---|---|---|---|
| NauseaGastrointestinal disorders | 28/49 | 30/41 | 69/91 |
| FatigueGeneral disorders | 16/49 | 21/41 | 30/91 |
| FatigueGastrointestinal disorders | 16/49 | 20/41 | 30/91 |
| Decreased AppetiteMetabolism and nutrition disorders | 22/49 | 19/41 | 32/91 |
| VomitingGastrointestinal disorders | 14/49 | 13/41 | 42/91 |
| AlopeciaSkin and subcutaneous tissue disorders | 10/49 | 5/41 | 42/91 |
| DiarrhoeaGastrointestinal disorders | 13/49 | 14/41 | 39/91 |
| ConstipationGastrointestinal disorders | 15/49 | 10/41 | 36/91 |
| AnaemiaBlood and lymphatic system disorders | 15/49 | 13/41 | 33/91 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/49 | 13/41 | 18/91 |
Baseline characteristics were assessed using the Safety Analysis Set.
| Age, Categorical(Participants) | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 27 | 27 | 55 | 109 |
| >=65 years | 22 | 14 | 36 | 72 |
| Age, Continuous(Years) | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated | Total |
|---|---|---|---|---|
| Mean | 62.2 ± 9.58 | 60.3 ± 10.22 | 60.3 ± 11.94 | 60.8 ± 10.94 |
| Sex: Female, Male(Participants) | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated | Total |
|---|---|---|---|---|
| Female | 19 | 19 | 60 | 98 |
| Male | 30 | 22 | 31 | 83 |
| Race (NIH/OMB)(Participants) | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 13 | 4 | 31 | 48 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 1 | 7 |
| White | 31 | 31 | 40 | 102 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 3 | 19 | 23 |
| Region of Enrollment(participants) | Cohort 1: HER2 Overexpressing | Cohort 1a: HER2 Overexpressing | Cohort 2: HER2 Mutated | Total |
|---|---|---|---|---|
| Netherlands | 10 | 8 | 13 | 31 |
| United States | 19 | 13 | 35 | 67 |
| Japan | 12 | 3 | 23 | 38 |
| France | 0 | 3 | 15 | 18 |
| Spain | 8 | 14 | 5 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from May 2018 to primary completion in May 2021, 35 months.
Results were first posted in May 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan
Carcinoma, Non-Small-Cell Lung →